Stella Thomassen, Department of Biochemistry, Cardiovascular Research Institute Maastricht, University Maastricht, 6200 MD Maastricht, the Netherlands, Tel.: +31 43 388 4160, Fax: +31 43 388 4159, E-mail:
Thromb Haemost. 2016 Mar;115(3):580-90. doi: 10.1160/TH15-04-0354. Epub 2015 Nov 26.
Tissue factor pathway inhibitor (TFPI) down-regulates the extrinsic coagulation pathway by inhibiting FXa and FVIIa. Both TFPI and FXa interact with several plasma proteins (e. g. prothrombin, FV/FVa, protein S) and non-proteinaceous compounds (e. g. phospholipids, heparin). It was our aim to investigate effects of ligands that bind to FXa and TFPI on FXa inhibition by full-length TFPI (designated TFPI) and truncated TFPI (TFPI1-150). Inhibition of FXa by TFPI and TFPI1-150 and effects of phospholipids, heparin, prothrombin, FV, FVa, and protein S thereon was quantified from progress curves of conversion of the FXa-specific chromogenic substrate CS11-(65). Low concentrations negatively charged phospholipids (~10 µM) already maximally stimulated (up to 5- to 6-fold) FXa inhibition by TFPI. Unfractionated heparin at concentrations (0.2-1 U/ml) enhanced FXa inhibition by TFPI ~8-fold, but impaired inhibition at concentrations > 1 U/ml. Physiological protein S and FV concentrations both enhanced FXa inhibition by TFPI 2- to 3-fold. In contrast, thrombin-activated FV (FVa) impaired the ability of TFPI to inhibit FXa. FXa inhibition by TFPI1-150 was not affected by FV, FVa, protein S, phospholipids and heparin. TFPI potently inhibited FXa-catalysed prothrombin activation in the absence of FVa, but hardly inhibited prothrombin activation in the presence of thrombin-activated FVa. In conclusion, physiological concentrations TFPI (0.25-0.5 nM TFPI) inhibit FXa with a t1/2 between 3-15 minutes. Direct FXa inhibition by TFPI is modulated by physiological concentrations prothrombin, FV, FVa, protein S, phospholipids and heparin indicating the importance of these modulators for the in vivo anticoagulant activity of TFPI.
组织因子途径抑制剂(TFPI)通过抑制 FXa 和 FVIIa 来下调外源性凝血途径。TFPI 和 FXa 均与几种血浆蛋白(如凝血酶原、FV/FVa、蛋白 S)和非蛋白类化合物(如磷脂、肝素)相互作用。我们的目的是研究与 FXa 和 TFPI 结合的配体对全长 TFPI(命名为 TFPI)和截断 TFPI(TFPI1-150)抑制 FXa 的影响。通过 FXa 特异性显色底物 CS11-(65)的转化过程中的进度曲线来定量测定 TFPI 和 TFPI1-150 对 FXa 的抑制作用以及磷脂、肝素、凝血酶原、FV、FVa 和蛋白 S 对其的影响。低浓度带负电荷的磷脂(~10 μM)已经最大程度地刺激(高达 5-6 倍)TFPI 对 FXa 的抑制作用。未分级的肝素在浓度(0.2-1 U/ml)下增强了 TFPI 对 FXa 的抑制作用约 8 倍,但在浓度>1 U/ml 时会损害抑制作用。生理蛋白 S 和 FV 浓度均使 TFPI 对 FXa 的抑制作用增强了 2-3 倍。相比之下,凝血酶激活的 FV(FVa)会损害 TFPI 抑制 FXa 的能力。FV、FVa、蛋白 S、磷脂和肝素对 TFPI1-150 抑制 FXa 没有影响。TFPI 强有力地抑制了 FXa 催化的凝血酶原激活,而在存在凝血酶激活的 FVa 时几乎不抑制凝血酶原激活。总之,生理浓度的 TFPI(0.25-0.5 nM TFPI)以 3-15 分钟之间的 t1/2 抑制 FXa。TFPI 对 FXa 的直接抑制作用受生理浓度的凝血酶原、FV、FVa、蛋白 S、磷脂和肝素的调节,这表明这些调节剂对 TFPI 在体内的抗凝活性非常重要。